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Abstract 
Background Residents of nursing homes and long-term care facilities are at a higher risk of outbreaks of 
influenza and of serious complications of influenza than those in the community. In late July 2005, a 
90-bed chronic care psycho-geriatric hospital in Sydney, Australia, reported cases of influenza-like illness 
(ILI) occurring amongst its residents. 
Methods An investigation to confirm the outbreak, and its cause, was undertaken. Influenza vaccination 
levels amongst residents, and the effects of antiviral drugs used for prevention and treatment, were 
assessed. Oseltamivir was only given to the residents, in the form of both treatment and prophylaxis. 
Results A total of 22 out of 89 residents met the clinical case definition of ILI with onset on or after 27 
July 2005. This represents an attack rate of 25%. Oseltamivir was commenced on day 9 of the outbreak. 
Influenza B was identified in six residents as the causative agent of the outbreak. No deaths or acute 
hospitalization were recorded for this outbreak and there were no further reported cases after the 
introduction of oseltamivir. Vaccine effectiveness was 75% and the strain of influenza B isolated was well 
matched to that year’s vaccine. 
Conclusions There are few data on the use of oseltamivir in influenza B outbreaks. Early antiviral 
intervention appeared to curtail this outbreak of influenza B in a chronic care facility. We found high 
vaccine effectiveness in this frail, institutionalized population, highlighting the importance of influenza 
vaccination for residents of chronic care facilities. 
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Background Residents of nursing homes and long-term care
facilities are at a higher risk of outbreaks of influenza and of
serious complications of influenza than those in the community.
In late July 2005, a 90-bed chronic care psycho-geriatric hospital
in Sydney, Australia, reported cases of influenza-like illness (ILI)
occurring amongst its residents.
Methods An investigation to confirm the outbreak, and its cause,
was undertaken. Influenza vaccination levels amongst residents,
and the effects of antiviral drugs used for prevention and
treatment, were assessed. Oseltamivir was only given to the
residents, in the form of both treatment and prophylaxis.
Results A total of 22 out of 89 residents met the clinical case
definition of ILI with onset on or after 27 July 2005. This
represents an attack rate of 25%. Oseltamivir was commenced on
day 9 of the outbreak. Influenza B was identified in six residents
as the causative agent of the outbreak. No deaths or acute
hospitalization were recorded for this outbreak and there were no
further reported cases after the introduction of oseltamivir.
Vaccine effectiveness was 75% and the strain of influenza B
isolated was well matched to that year’s vaccine.
Conclusions There are few data on the use of oseltamivir in
influenza B outbreaks. Early antiviral intervention appeared to
curtail this outbreak of influenza B in a chronic care facility. We
found high vaccine effectiveness in this frail, institutionalized
population, highlighting the importance of influenza vaccination
for residents of chronic care facilities.
Keywords Influenza, oseltamivir, antiviral, hospital, vaccination,
outbreak.
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Introduction
Residents of facilities such as nursing homes and long-stay
hospitals are at a higher risk of influenza outbreaks than
people living in the wider community. They are especially
susceptible because of their frailty, increased age and the
presence of multiple co-morbidities. In addition, the closed
conditions of the facilities, the close proximity in which the
residents live and the frequent contact with staff, volunteers
and to a less extent visitors may contribute to the rapid
transmission of virus during outbreaks.1 When influenza
outbreaks occur in these facilities, attack rates can range
from 10% to 70%;2,3 with hospitalization occurring in
more than half of ill residents, and death resulting in 30%
of cases.4–6 Although more severe disease is associated with
influenza A outbreaks, influenza B has also been associated
with considerable morbidity and mortality, despite
the availability of annual influenza vaccines for several
decades.7
Neuraminidase inhibitors (NI), such as oseltamivir and
zanamvir are useful in the treatment and prophylaxis of
influenza virus infections. A double blinded randomized
control trial of highly vaccinated long-term care residents
verified that oseltamivir pre-exposure prophylaxis led to a
92% reduction in the incidence of laboratory-confirmed
influenza (P < 0Æ01).8 Although the efficacy of post-expo-
sure prophylaxis with influenza antivirals, especially in
these facilities, has not yet been established, observational
studies have reported that they are effective in controlling
influenza outbreaks.9,10 Early administration (within
48 hours of first symptoms) of these products has been
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overall risk of complications by 25–40%.11–13 However,
many unsolved issues remain regarding outbreak control
and the use of antivirals, and as such the use of antivirals
during outbreaks in closed environments is still limited in
many countries.14
On 30 July 2005, public health authorities in Sydney,
Australia, were informed of an outbreak of respiratory ill-
ness in a long-term care psycho-geriatric hospital. The
Public Health Unit invited researchers from the National
Centre for Immunisation Research and Surveillance to
study the role of vaccination and antiviral use during the
outbreak. The overall aim of the investigation was to con-
firm the presence of an outbreak, to determine the causa-
tive agent and to control the outbreak.
Methods
Epidemiological investigation
An influenza outbreak was identified on 30 July 2005 in a
long-term care psycho-geriatric hospital. This hospital pro-
vides long-term care for confused and disturbed elderly res-
idents, for terminally ill patients and those with spinal
conditions. Its other specialities are in the geriatric rehabili-
tation, aged care, respite, transit and psychiatric areas. At
the time of the outbreak, the facility had 89 residents
including 49 female and 40 male residents, with a median
age of 78Æ3 years (range: 35–98 years) (Table 1). The facility
was divided into five units, which were located in three
separate buildings. Residents from units A, B and C had no
access to the rest of the facility. Units D and E were located
in the same building but on different floors, and both
accommodated frail aged residents. Figure 1 shows the lay-
out of the facility and the timeline of outbreak activity.
Each unit had a communal living area and dining room.
Case definition for influenza-like-illness (ILI)
Cases of influenza in the hospital were identified using the
following case definition: any resident or staff member with
fever plus at least two other symptoms (cough, rigours or
chills, prostration and weakness, myalgia or widespread
aches and pains) and having an onset date on or after 27
July 2005.
Case finding
A standard data collection tool was used to collect infor-
mation for residents who met the case definition. Data col-
lected on the symptomatic residents included demographic
information, symptoms, prophylaxis, vaccination, underly-
ing medical conditions, antibiotic use, hospitalization and
death. Similar data were also collected on some of the
asymptomatic residents. Receipt of the influenza vaccine in
the year of the outbreak was verified against the hospital
charts.
At the time of the outbreak, the investigation team col-
lected data on 58 of the 89 residents, which included all
residents who reported having an ILI, and 36 residents who
were asymptomatic. We also collected information from 23
staff members. As staff vaccination records were not rou-
tinely collected by the hospital at the time of the outbreak,
we were unable to (i) verify their vaccination history; and
(ii) calculate the overall level of staff vaccination in hospital
prior to the outbreak.
Public health measures
The Sydney West public health unit was notified of the
outbreak 4 days after the onset of symptoms of the first
Table 1. Demographic information relating to residents of the
hospital in Sydney, Australia, July 2005
Characteristics n = 89 (%)
Male 40 (44Æ9)
Female 49 (55Æ1)
£65 years 39 (43Æ8)
>65 years 50 (56Æ2)
Living in unit
Unit A 16 (18Æ0)
Unit B 10 (11Æ2)
Unit C 16 (18Æ0)
Unit D 21 (23Æ6)
Unit E 26 (29Æ2)
Co-morbidities
Huntington’s disease 16 (18Æ0)
Dementia 16 (18Æ0)
Other psycho-geriatric disorders 10 (11Æ2)
Symptoms
Acute respiratory 24 (27Æ0)
Met ILI case definition 22 (24Æ7)
Vaccinated




















Figure 1. Layout of the hospital and timeline of events.
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case. Recommendations made to the nursing home
included the use of respiratory infection control precau-
tions, cohorting of sick residents, ensuring staff were
restricted to the units where they were working, restricting
visitors to the facility and postponing trips from the
facility.
Of immediate concern was the low rate of vaccination
amongst residents. The treating general practitioner was
contacted and requested to expedite the administration of
influenza vaccine to those who were not vaccinated. Osel-
tamivir was offered as either treatment to sick residents at
75 mg twice daily for 5 days, or prophylaxis to asymptom-
atic residents with 75 mg once daily for 10 days. Oseltami-
vir was not offered to staff members.
Statistical analysis
Data collected were entered and analysed descriptively
using Epi-info, CDC, USA (version 3.3.2). Descriptive sta-
tistics was used to describe age, symptoms, vaccination
rates and hospitalization. Attack rates in residents were cal-
culated by dividing the number of cases in residents by the
total number of residents on the first day of the outbreak
(day 0). Vaccine effectiveness in residents was calculated as
follows: 1 minus the ratio of attack rate in the vaccinated
to the attack rate in the unvaccinated.
Laboratory investigation
Specimens for laboratory testing were taken on two occa-
sions. The public health unit initially collected nose and ⁄ or
throat swabs from residents who displayed an ILI on 30
July 2005. Twenty-two swabs were collected by the public
health unit and tested within 24 hours. Nose and throat
swabs were also collected by the study team on 1 August
2005, from all residents residing in four of the five units,
which included both symptomatic and asymptomatic resi-
dents. The study team received these results on 21 Septem-
ber 2005. Direct immunofluorescence was performed on
smears of deposits from nose and throat swabs that were
acetone-fixed and stained with fluorescein-conjugated
monoclonal antibodies against influenza A and B haemag-
glutinin and nucleoprotein, respiratory syncytial virus,
parainfluenza viruses and adenovirus (Chemicon Interna-
tional, Temecula, CA, USA).15
Results
Over a 9-day period, 24 of 89 residents (27%) displayed
acute respiratory symptoms and 22 met the case definition
of ILI, with malaise and cough being the two most fre-
quently reported symptoms. Onset of illness occurred
between 27 July and 6 August 2005, with a peak of 17
case-residents in the period between 31 July and 3 August
2005 (Figure 2). The overall attack rate for the hospital was
25%. For units A, B and C it was 68.8%, 90% and 12.5%
respectively. There were no cases in either D or E unit.
There were no cases of pneumonia, hospitalization or death
among the residents due to influenza.
Oseltamivir was offered as either treatment to sick resi-
dents or prophylaxis to asymptomatic residents. This was
commenced on 6 August 2005 and was taken by 97%
(86 ⁄ 89) of the residents. Of these, 87% (77 ⁄ 89) were given
oseltamivir prophylaxis and 10% (9 ⁄ 89) were actively trea-
ted. Three of the residents refused to take the drug. Of the
residents who reported having ILI, 13 had already been ill
for longer than 48 hours, but were offered oseltamivir as a
precaution. The average number of days from onset of ill-
ness to the initiation of oseltamivir for the units that
reported ILI cases was 4Æ6 days. However, this ranged from
1 day for unit C to 7 days for unit B. The hospital did not
report any adverse events occurring in the residents follow-
ing the administration of the antiviral; however, only low
levels of surveillance were undertaken. One resident did
discontinue the use of the drug due to feeling nausea. This
patient was undergoing cancer treatment at the time of the
outbreak, so we could verify whether it was linked to the
drug. Staff members were not offered oseltamivir. As docu-
mented in Table 2, there were no further cases after osel-
tamivir prophylaxis and treatment was commenced.
Residents living in unit B had the highest relative risk of
contracting the virus compared with the other units [rela-
tive risk: 5Æ47, 95% confidence intervals (CI): 3Æ19–9Æ37,
P < 0Æ001]. For all units a strong association also existed
between age (65 years and older) and being diagnosed with
influenza (relative risk: 2Æ30, 95% CI: 1Æ10–4Æ79, P = 0Æ02)
(Table 3).
Of the 58 residents for whom information was collected,


























































































Figure 2. Epidemic curve for influenza-like-illness cases among
residents of the hospital, July and August 2005.
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outbreak. The ILI attack rate was lower in the vaccinated
compared to unvaccinated residents (13Æ9% versus 55Æ2%)
and the vaccine effectiveness for this group of residents was
75% (95% CI: 0Æ06–1Æ47). At the time of the outbreak,
there was 170 nursing, medical, ancillary and support staff
working in the facility. The attack rate of acute respiratory
illness among all staff members was 1Æ2% (2 ⁄ 170), although
none fulfilled the criteria of an ILI. No antiviral treatment,
prophylaxis or vaccine was given to staff members. How-
ever, staff members were restricted to the units where they
were working.
Laboratory investigations
Influenza B was detected in six combined nose and throat
swabs taken from the residents. No influenza A or other
respiratory viruses were detected. One influenza isolate was
subtyped as influenza B ⁄ Shanghai ⁄ 361 ⁄ 2002-like, which
was well matched to the influenza B strain contained in the
2005 influenza vaccine.16 Of the residents who had a labo-
ratory-confirmed illness, all of them met the ILI definition
and five had received the vaccine that year.
Discussion
We describe an influenza B virus outbreak that affected 25%
of residents of a chronic care hospital. The outbreak started
on 27 July 2005 with a single ILI case and extended to 21 ⁄ 89
of the residents within a week. The public health unit was
notified 4 days after the onset of the first symptoms.
To the best of our knowledge, there is very little pub-
lished literature available on the effectiveness of oseltamivir
in the control of influenza B outbreaks in long-term care
facilities (LTCFs). One of the few available comparator
studies concluded that prophylaxis was very effective in
halting the outbreak.10 During our outbreak, oseltamivir
was offered as either treatment to sick residents or prophy-
laxis to asymptomatic residents. After the prophylaxis was
initiated on 6 August 2005 there were no more cases. We
are however unable to conclude whether the cessation of
cases was because of the initiation of the drug or due to
the outbreak was already started to wane. No major side
effects from the use of oseltamivir in this population were
reported in this outbreak.
In this outbreak, there was a delay of over a week
between the notification and the initiation of prophylaxis.
It is recommended by the Centers for Disease Control and
Prevention’s Advisory Committee on Immunisation Prac-
tices that when a confirmed or suspected outbreak of influ-
enza occurs in institutions that house persons at high risk,
chemoprophylaxis should be started as early as possible.17
A recent example of the effects of early initiation of post-
exposure chemoprophylaxis was discussed in a paper by
Rubin et al.18 The authors found that LTCFs that initiated
chemoprophylaxis >5 days after outbreak onset had signifi-
cantly longer duration of outbreaks (18Æ3 versus 6Æ7 days;
P < 0Æ001), higher incidence rates (10Æ5 cases ⁄ 100 residents
versus 6Æ2 cases ⁄ 100 residents; P < 0Æ023) and higher case-
fatality rates (3Æ3 deaths ⁄ 100 residents with influenza A ver-
sus 0Æ45 deaths ⁄ 100 residents with influenza A; P < 0Æ005)
than did LTCFs that initiated chemoprophylaxis £5 days
after outbreak onset. Their findings make sense: the earlier
the diagnosis, the quicker the introduction of barriers to
transmission (such as speedier chemoprophylaxis initia-
tion), the lower the number of new vectors, and the lower
the impact and extent of an influenza outbreak.19
Table 2. Summary of the antiviral agent usage on affected units
during the outbreak in the hospital
Characteristics
Unit A Unit B Unit C
n n n






No. residents who received oseltamivir for
Treatment 4 0 5







Time from onset of first case
to initiation of oseltamivir (days)
6 7 1
Attack rate (no. cases ⁄ total
no. residents) (%)
68Æ8 90Æ0 12Æ5
No. case residents with
pneumonia ⁄ serious complication
0 0 0
Table 3. Univariate analysis for residents who met the influenza-










Gender 0Æ98 0Æ47 2Æ02 0Æ95 0Æ00
Received current
influenza vaccine
0Æ94 0Æ47 1Æ86 0Æ85 0Æ04
Location
Unit A 4Æ56 2Æ41 8Æ63 <0Æ001 20Æ32
Unit B 5Æ47 3Æ19 9Æ37 <0Æ001 25Æ80
Unit C 0Æ46 0Æ12 1Æ76 0Æ21 1Æ57
Age above
65 years
2Æ30 1Æ10 4Æ79 0Æ02 5Æ62
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The efficacy of treatment with NI is highly dependent on
the time of treatment initiation.20 Aoki et al.20 analysed the
relative improvement in symptoms by the interval between
onset of symptoms and treatment. Patients who started
receiving treatment 48 hours after the onset of symptoms
served as the control group. For the patients who started
receiving treatment within 6 hours after the onset of symp-
toms, the duration of impaired activity was reduced by
6 days, the duration of impaired health was reduced by
3Æ5 days and the duration of fever was reduced by 2Æ5 days,
compared with the observations for control subjects. The
magnitude of the benefit decreased progressively with
increases in the delay until initiation of treatment. There-
fore, the benefits of treatment are maximized when early
treatment is provided. In a retrospective evaluation of osel-
tamivir use during influenza outbreaks in nursing homes in
Ontario, Canada, patients who received oseltamivir within
48 hours after the onset of symptoms were compared with
patients who received either no therapy or therapy with
amantadine. Patients who received oseltamivir were less
likely to be prescribed antibiotics, to be hospitalized or to
die (P < 0Æ05, for each outcome).21
The use of influenza vaccination for elderly people who
have chronic disease and for residents in long-term care
institutions is also strongly recommended by the Center for
Disease Control and Prevention in the United States.17 In
Australia, the influenza vaccine is recommended by the
Australian government and free to anyone over the age of
65 years.22 For residents in long-term care institutions, the
vaccine is thought to be around 30–40% effective in pre-
venting upper respiratory illness2 and effective in prevent-
ing 50–60% of hospitalizations or secondary
complications.23 However, with regard to preventing mor-
tality, there has been recent controversy about the level of
effectiveness in elderly people. Previously it was docu-
mented that the vaccine was effective in preventing 68% of
deaths (17). However, the evidence base for this consisted
mainly of observational studies which compared the mor-
tality risks in self-selected groups of vaccinated and unvac-
cinated elderly people. Simonsen et al. suggested that high
estimates of influenza vaccine effectiveness for severe out-
comes are best explained by an unrecognized selection bias
in cohort studies.24
Numerous accounts of influenza outbreaks in aged care
facilities (ACFs) and hospital wards have identified staff ill-
ness preceding resident illness.25,26 In this outbreak, the
original source of the illness was not determined; however,
it was thought that it might have originated from a staff
member who had recently travelled from overseas. In the-
ory, vaccination of anyone who will enter the facilities will
result in a reduced rate of introduction of influenza and,
thus, in a reduction in the risk of outbreaks. Staff vaccina-
tion has been suggested to be as at least as important as
resident vaccination in preventing outbreaks.17,27 Salgado
et al. demonstrated that low levels of healthcare workers
(HCW) vaccination significantly correlated to an increased
rate of nosocomial influenza infections in hospitalized
patients.28 In another study conducted in 12 different long-
term care hospitals, HCWs were randomized to either
receive the influenza vaccine or not. In hospitals where
HCWs were offered vaccination, 61% of 1078 workers were
vaccinated. The study reported that vaccination of the
HCWs was associated with reductions in total patient mor-
tality from 17% to 10% and a reduction in ILI.29
Identification of an influenza outbreak in a long-term
care facility provides an ongoing challenge. Early identifi-
cation and management of outbreaks may be hampered
by the size and conditions of the ACF, the health and
age of residents and the difficulties of contacting multiple
primary care doctors. There is currently a lack of con-
sensus about how to perform influenza surveillance or
whether it is practical and cost-effective to do so system-
atically.
Active surveillance where there is regular routine contact
with the ACF and includes zero-case reporting instead of
awaiting passive reporting, complemented by early detec-
tion with point-of-care testing has been shown to result in
better outbreak control.30 Point-of-care tests are less sensi-
tive (63–81%) than traditional laboratory tests such as
direct immunofluorescence and nucleic acid testing, but are
highly specific (82–100%).31–33 They are useful for identifi-
cation of influenza outbreaks,34 for example, when per-
formed on specimens from the first few cases in a cluster
of respiratory illness.35
Prevention and control systems for influenza virus out-
breaks in LTCFs rely on a certain amount of knowledge,
interest, resources and compliance by the facilities and their
staff. While maintaining high annual vaccination coverage
for the elderly and other residents and promoting increased
vaccination rate among staff members remains an
important method of reducing the impact of influenza,
oseltamivir has the potential of being a safe and cost-effec-
tive control measure for outbreaks.
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